一分钟看懂
这是一项关于Carcinoma, Renal Cell的I 期 / II 期研究，登记的药物或干预包括PF-08634404；Ipilimumab；Axitinib；Casdatifan，当前状态为招募中。登记地点显示中国北京、重庆、武汉、长沙等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
PF-08634404；Ipilimumab；Axitinib；Casdatifan · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Cancer hospital · 北京
- Chongqing University Cancer Hospital · 重庆
- Union Hospital Tongji Medical College Huazhong University of Science and Technology · 武汉
- Hunan Cancer Hospital · 长沙
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School · 南京
- Qilu Hospital of Shandong University · 济南
- The first affiliated hospital of Ningbo university · 宁波
公开的入选条件
- * 18 years of age or older at screening
- * Locally advanced (not amenable to curative surgery or radiation therapy) or metastatic RCC with diagnosis confirmed by histology/cytology
- * At least one measurable (as defined by the investigator) and untreated lesion
- * Adequate hematologic, hepatic, cardiac and renal function
- * No prior systemic therapy for RCC (immunotherapy after surgery is allowed if received \>12 months prior)
- * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- * All International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) based risk categories
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07227415；登记信息更新于 2026-09-17。